Clinical-scale single-step CD4+ and CD8+ cell depletion for donor innate lymphocyte infusion (DILI)

Bone Marrow Transplantation

Volumn 41, Issue 7, 2008, Pages 643-650

  Smetak, M ^a   Kimmel, B ^b   Birkmann, J ^a   Schaefer Eckart, K ^a   Einsele, H ^b   Wilhelm, M ^a   Kunzmann, V ^b  

^a KLINIKUM NÜRNBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DONOR INNATE LYMPHOCYTE INFUSION; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; INNATE IMMUNITY; LEUKAPHERESIS; LYMPHOCYTE TRANSFUSION; NATURAL KILLER CELL; PRIORITY JOURNAL; T CELL DEPLETION;

EID: 42149192511     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705942     Document Type: Article

References (62)

1. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
2. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
3. Collins Jr RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-516.
4. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412.
5. Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B et al. Randomized trial of CD8 + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625-632.
6. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
7. Gugllelmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100 397-405.
8. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
9. Born WK, Reardon CL, O'Brien RL. The function of gammadelta T cells in innate immunity. Curr Opin Immunol 2006; 18: 31-38.
10. Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. Int Arch Allergy Immunol 2001; 125: 256-263.
11. Nanno M, Seki H, Mathioudakis G, Suzuki R, Itoh K, Ioannides CG et al Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors. Eur J Immunol 1992; 22: 679-687.
12. Poupot M, Pont F, Fournie JJ. Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human gamma delta T cells to anaplastic large cell lymphoma. J Immunol 2005; 174 1717-1722.
13. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by amino-bisphophonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96 384-392.
14. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 2004; 173: 6767-6776.
15. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol 1995; 154: 3932-3940.
16. Bachelez H, Flageul B, Degos L, Boumsell L, Bensussan A. TCR gamma delta bearing T lymphocytes infiltrating human primary cutaneous melanomas. J Invest Dermatol 1992; 98: 369-374.
17. Zocchi MR, Ferrarini M, Rugarli C. Selective lysis of the autologous tumor by delta TCS1 + gamma/delta + tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol 1990; 20: 2685-2689.
18. Thomas ML, Samant UC, Deshpande RK, Chiplunkar SV. Gammadelta T cells lyse autologous and allogenic oesophageal tumours: Involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunol Immunother 2000; 48: 653-659.
19. Watanabe N, Hizuta A, Tanaka N, Orita K. Localization of T cell receptor (TCR)-gamma delta + T cells into human colorectal cancer: Flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes. Clin Exp Immunol 1995; 102: 167-173.
20. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200-206.
21. Kunzmann V, Wilhelm M. Anti-lymphoma effect of gamma-delta T cells. Leuk Lymphoma 2005; 46: 671-680.
22. Alyea EP, Canning C, Neuberg D, Daley H, Houde H, Giralt S et al. CD8 + cell depletion of donor lymphocyte infusions using CD8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: A pilot study. Bone Marrow Transplant 2004; 34: 123-128.
23. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
24. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D- et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
25. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
26. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996-4003.
27. Baron F, Frere P, Baudoux E, Schaaf-Lafontaine N, Fillet G, Beguin Y. Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. Haematologica 2003; 88: 835-837.
28. Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 2005; 35: 637-643.
29. Schilbach KE, Geiselhart A, Wessels JT, Niethammer D, Handgretinger R. Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother 2000; 23: 536-548.
30. Lamb Jr LS, Musk P, Ye Z, van RF, Geier SS, Tong JJ et al. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 2001; 27: 601-606.
31. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
32. Drobyski WR, Majewski D, Hanson G. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs host disease. Biol Blood Marrow Transplant 1999; 5: 222-230.
33. Blazar BR, Taylor PA, Bluestone JA, Vallera DA. Murine gamma/ delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens. Blood 1996; 87: 4463-4472.
34. Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J et al. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. Bone Marrow Transplant 1997; 19 1069-1077.
35. Nagai M, Azuma E, Qi J, Kumamoto T, Hiratake S, Hirayama M et al. Suppression of alloreactivity with gamma delta T-cells: Relevance to increased gamma delta T-cells following bone marrow transplantation. Biomed Pharmacother 1998; 52: 137-142.
36. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39: 751-757.
37. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
38. Schumm M, Handgretinger R, Pfeiffer M, Feuchtinger T, Kuci S, Faul C et al. Determination of residual T- and B-cell content after immunomagnetic depletion: Proposal for flow cytometric analysis and results from 103 separations. Cytotherapy 2006; 8: 465-472.
39. Lang P, Pfeiffer M, Handgretinger R, Schumm M, Demirdelen B, Stanojevic S et al. Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. Bone Marrow Transplant 2002; 29: 497-502.
40. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835-1838.
41. King KM, Chan WS, Preti RA, Musk P, Lamb LS. Depletion of alphabeta+ T cells for cellular therapy of leukemia using gammadelta T cell enriched donor leukocyte infusion. Cytotherapy 2003; 5: 454 (abstract 78).
42. Otto M, Barfield RC, Iyengar R, Gatewood J, Muller I, Holladay MS et al. Human garnmadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Immunother 2005; 28: 73-78.
43. Barfield RC, Otto M, Houston J, Holladay M, Geiger T, Martin J et al A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004; 6: 1-6.
44. Jansen J, Hanks S, Akard LP, Thompson JM, Burns S, Chang Q et al. Immunomagnetic CD4+ and CD9+ cell depletion for patients at high risk for severe acute GVHD. Bone Marrow Transplant 1996; 17: 377-382.
45. Martin PJ, Rowley SD, Anasetti C, Chauncey TR, Gooley T, Petersdorf EW et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999; 94: 2192-2199.
46. Herrera C, Torres A, Garcia-Castellano JM, Roman J, Martin C, Serrano J et al. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Bone Marrow Transplant 1999; 23: 443-450.
47. Haas W, Pereira P, Tonegawa S. Gamma/delta cells. Annu Rev Immunol 1993; 11: 637-685.
48. Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol 1989; 44: 265-311.
49. Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S et al. Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology 2005; 116: 354-361.
50. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562.
51. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
52. Sutmuller RP, van Duivenvoorde LM, van EA, Schumacher TN, Wildenberg ME, Allison JP et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-832.
53. Young KJ, Kay LS, Phillips MJ, Zhang L Antitumor activity mediated by double-negative T cells. Cancer Res 2003; 63: 8014-8021.
54. Singh B, Read S, Asseman C, Malmstrom V, Mottet C, Stephens LA et al Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001; 182: 190-200.
55. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
56. Young KJ, DuTemple B, Phillips MJ, Zhang L. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol 2003; 171: 134-141.
57. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identification of a previously unknown antigen-specific regulatory T ceil and its mechanism of suppression. Nat Med 2000; 6: 782-789.
58. Fischer K, Voelkl S, Heymann J, Przybylski GK, Mondal K, Laumer M et al. Isolation and characterization of human antigen-specific TCR alpha beta + CD4(-)CD8- double-negative regulatory T cells. Blood 2005; 105: 2828-2835.
59. Priatel JJ, Utting O, Teh HS. TCR/self-antigen interactions drive double-negative T cell peripheral expansion and differentiation into suppresor cells. J Immunol 2001; 167: 6188-6194.
60. Chen W, Ford MS, Young KJ, Cybulsky MI, Zhang L. Role of double-negative regulatory T cells in long-term cardiac xenograft survival. J Immunol 2003; 170: 1846-1853.
61. Chen W, Zhou D, Torrealba JR, Waddell TK, Grant D, Zhang L. Donor lymphocyte infusion induces long-term donor-specific cardiac xenograft survival through activation of recipient double-negative replatory T cells. J Immunol 2005; 175: 3409-3416.
62. Young KJ, DuTemple B, Zhang Z, Levy G, Zhang L. CD4(-)CD8(-) regulatory T cells implicated in preventing graft-versus-host and promoting graft-versus-leukemia responses. Transplant Proc 2001; 33: 1762-1763.